155 related articles for article (PubMed ID: 1854508)
21. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
[TBL] [Abstract][Full Text] [Related]
22. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide.
Imtiaz KE; Monteith P; Khaleeli A
Clin Endocrinol (Oxf); 2000 Dec; 53(6):755-8. PubMed ID: 11155099
[TBL] [Abstract][Full Text] [Related]
23. Lung carcinoid with Cushing's syndrome: control of serum ACTH and cortisol levels using SMS 201-995 (sandostatin).
Hearn PR; Reynolds CL; Johansen K; Woodhouse NJ
Clin Endocrinol (Oxf); 1988 Feb; 28(2):181-5. PubMed ID: 2844445
[TBL] [Abstract][Full Text] [Related]
24. Long-term survival in a patient with malignant carcinoid treated with high-dose octreotide.
Deguchi H; Deguchi K; Tsukada T; Murashima S; Iwasaki E; Tsuda M; Kobayashi T; Shirakawa S
Intern Med; 1994 Feb; 33(2):100-2. PubMed ID: 7517229
[TBL] [Abstract][Full Text] [Related]
25. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
[TBL] [Abstract][Full Text] [Related]
26. Carcinoid of the pancreas.
Migliori M; Tomassetti P; Lalli S; Casadei R; Santini D; Corinaldesi R; Gullo L
Pancreatology; 2002; 2(2):163-6. PubMed ID: 12123097
[TBL] [Abstract][Full Text] [Related]
27. [Enteral hyperoxalosis due to therapy with a somatostatin analog].
Ranft K; Eibl-Eibesfeldt B
Dtsch Med Wochenschr; 1990 Feb; 115(5):179-81. PubMed ID: 2298134
[TBL] [Abstract][Full Text] [Related]
28. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
[TBL] [Abstract][Full Text] [Related]
29. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors.
Sywak MS; Pasieka JL; McEwan A; Kline G; Rorstad O
World J Surg; 2004 Nov; 28(11):1157-62. PubMed ID: 15490060
[TBL] [Abstract][Full Text] [Related]
30. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
31. The octreotide suppression test and [111In-DTPA-D-Phe1]-octreotide scintigraphy in neuroendocrine tumours correlate with responsiveness to somatostatin analogue treatment.
Shi W; Buchanan KD; Johnston CF; Larkin C; Ong YL; Ferguson R; Laird J
Clin Endocrinol (Oxf); 1998 Mar; 48(3):303-9. PubMed ID: 9578820
[TBL] [Abstract][Full Text] [Related]
32. [Treatment of gastrointestinal neuroendocrine tumors with the somatostatin analog octreotide (Sandostatin)].
Stöckmann F; Creutzfeldt W
Z Gastroenterol; 1988 Oct; 26(10):665-75. PubMed ID: 2849248
[TBL] [Abstract][Full Text] [Related]
33. [Symptomatic treatment of the malignant carcinoid syndrome with octreotide].
Alberts AS; Falkson G
S Afr Med J; 1989 Jan; 75(1):30-1. PubMed ID: 2911781
[TBL] [Abstract][Full Text] [Related]
34. The tumour vanishes.
Todd JF; Meeran K
Clin Endocrinol (Oxf); 2000 Dec; 53(6):663-4. PubMed ID: 11155085
[No Abstract] [Full Text] [Related]
35. Octreotide therapy in carcinoid disease.
Bax ND; Woods HF; Batchelor A; Jennings M
Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
[TBL] [Abstract][Full Text] [Related]
36. [Metastasized carcinoid tumor treated with interferon and octreotide].
Szilvás A; Székely G; Szilvási I; Jakab F
Orv Hetil; 1998 Oct; 139(41):2455-8. PubMed ID: 9805460
[TBL] [Abstract][Full Text] [Related]
37. Use of somatostatin analog in management of carcinoid syndrome.
Vinik A; Moattari AR
Dig Dis Sci; 1989 Mar; 34(3 Suppl):14S-27S. PubMed ID: 2920654
[TBL] [Abstract][Full Text] [Related]
38. Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors.
Arnold R; Neuhaus C; Benning R; Schwerk WB; Trautmann ME; Joseph K; Bruns C
World J Surg; 1993; 17(4):511-9. PubMed ID: 8395752
[TBL] [Abstract][Full Text] [Related]
39. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
Shi YF; Harris AG; Zhu XF; Deng JY
Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
[TBL] [Abstract][Full Text] [Related]
40. The effect of a somatostatin analogue on the release of hormones from human midgut carcinoid tumour cells.
Wängberg B; Nilsson O; Theodorsson E; Dahlström A; Ahlman H
Br J Cancer; 1991 Jul; 64(1):23-8. PubMed ID: 1713051
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
